Recently, it was observed that therapeutic interventions aimed at increasing circulating HDL and ApoA1 levels improved hyperglycemia and attenuated IR in db/db mice, a genetic model of T2DM [101], thereby opening the possibility to consider insulin or insulin-sensitizers to correct metabolic dysfunctions by improving insulin sensitivity and enhancing glucose therapy in the AIP context. This evidence concerns the gene INS and Hyperglycemia.